The global clinical nutrition market was valued at $39,339.4 million in 2015, and it is expected to grow at a CAGR of 5.4% during 2016 - 2022. The factors driving the growth of the global market include increasing geriatric population, high birth rate and high number of premature birth, surge in the number of victims of malnutrition receiving treatment, surging incidence of lifestyle associated disease, and increasing incidence of cancer and central nervous system diseases. Malnutrition is a widespread problem, affecting the lives of millions of people globally. It is a condition that occurs due to deficiency of essential nutrients in the body. In 2010, around 40% of all hospital patients globally were malnourished.
Clinical nutrition is the most efficient way to treat malnutrition and helps in avoiding associated costs. In Europe, around one-third of all hospital patients were malnourished in 2012. The increase in the number of victims of malnutrition globally, is expected to result in an increased usage of healthcare resource due to the longer stays in hospitals. As per an article of 2012, the malnutrition cost European government up to USD 237.0 billion a year; while the clinical nutrition accounted for about 2.5% of the cost involved with malnutrition.
The increasing incidence of cancer and central nervous system (CNS) diseases is driving the growth of the global enteral nutrition market. Enteral nutrition products are considered to be one of the best alternatives during the treatment of cancer and CNS diseases, to avoid nutrition deficiency in human body, for optimal functioning of various organs. Cancer can change the metabolism of nutrient uptake in patient’s body, therefore they require good nutrition. Cancer may lead to malnutrition and weight loss; therefore, patients are required continuous nutrient feeding. Enteral nutrition is one of the best solutions to the problem. According to the WHO, there were 14.1 million new cancer cases, 8.2 million cancer deaths and 32.6 million people living with cancer (within 5 years of diagnosis) in 2012 globally. The organization also reported that 57% (8 million) of new cancer cases, 65% (5.3 million) of the cancer deaths and 48% (15.6 million) of the 5-year prevalent cancer cases occurred in the less developed regions.
In 2015, Asia-Pacific held the largest share in the global clinical nutrition market with 40.4% share. The region is anticipated to witness rapid growth during the forecast period. The increasing birth rate, along with growing geriatric population and high number of people with malnutrition is driving the growth of the clinical nutrition market in the region. The total number of people aged 65 years and above in Asia-Pacific was estimated at 288.0 million in 2010. This number is expected to reach 911.0 million by 2050. Additionally, the increasing number of malnutrition treatment cases in the region is expected to increase the demand for clinical nutrition products.
Moreover, with the increasing disposable income, increasing healthcare expenditure, and increasing awareness regarding nutrition is anticipated to fuel the growth of the Asia-Pacific clinical nutrition market. The different governments in the region are running awareness programs throughout these countries to encourage people for consuming nutritional diet. This would indirectly support the growth of the clinical nutrition market in the region.
Some of the major players operating in the global clinical nutrition market include Baxter International Inc., Abbott Laboratories, B. Braun Melsungen AG, Nestlé S.A., Groupe Danone, Mead Johnson Nutrition Company, Fresenius Kabi AG, and Perrigo Company Plc.
Clinical nutrition is the most efficient way to treat malnutrition and helps in avoiding associated costs. In Europe, around one-third of all hospital patients were malnourished in 2012. The increase in the number of victims of malnutrition globally, is expected to result in an increased usage of healthcare resource due to the longer stays in hospitals. As per an article of 2012, the malnutrition cost European government up to USD 237.0 billion a year; while the clinical nutrition accounted for about 2.5% of the cost involved with malnutrition.
The increasing incidence of cancer and central nervous system (CNS) diseases is driving the growth of the global enteral nutrition market. Enteral nutrition products are considered to be one of the best alternatives during the treatment of cancer and CNS diseases, to avoid nutrition deficiency in human body, for optimal functioning of various organs. Cancer can change the metabolism of nutrient uptake in patient’s body, therefore they require good nutrition. Cancer may lead to malnutrition and weight loss; therefore, patients are required continuous nutrient feeding. Enteral nutrition is one of the best solutions to the problem. According to the WHO, there were 14.1 million new cancer cases, 8.2 million cancer deaths and 32.6 million people living with cancer (within 5 years of diagnosis) in 2012 globally. The organization also reported that 57% (8 million) of new cancer cases, 65% (5.3 million) of the cancer deaths and 48% (15.6 million) of the 5-year prevalent cancer cases occurred in the less developed regions.
 |
| To receive a free sample copy of this report |
Moreover, with the increasing disposable income, increasing healthcare expenditure, and increasing awareness regarding nutrition is anticipated to fuel the growth of the Asia-Pacific clinical nutrition market. The different governments in the region are running awareness programs throughout these countries to encourage people for consuming nutritional diet. This would indirectly support the growth of the clinical nutrition market in the region.
Some of the major players operating in the global clinical nutrition market include Baxter International Inc., Abbott Laboratories, B. Braun Melsungen AG, Nestlé S.A., Groupe Danone, Mead Johnson Nutrition Company, Fresenius Kabi AG, and Perrigo Company Plc.
